Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Neurocrine Bioscienc (NBIX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,660,805
  • Shares Outstanding, K 91,287
  • Annual Sales, $ 451,240 K
  • Annual Income, $ 21,110 K
  • 60-Month Beta 1.46
  • Price/Sales 17.01
  • Price/Cash Flow 167.72
  • Price/Book 18.75

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate 0.27
  • Number of Estimates 10
  • High Estimate 0.64
  • Low Estimate 0.02
  • Prior Year -0.07
  • Growth Rate Est. (year over year) +485.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
75.90 +12.98%
on 05/20/19
86.58 -0.95%
on 06/17/19
+6.72 (+8.51%)
since 05/17/19
3-Month
71.85 +19.35%
on 04/30/19
91.98 -6.77%
on 04/10/19
+1.36 (+1.62%)
since 03/15/19
52-Week
64.72 +32.50%
on 12/12/18
126.98 -32.47%
on 09/13/18
-16.57 (-16.19%)
since 06/15/18

Most Recent Stories

More News
Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) and Opicapone at the 2019 World Congress on Parkinson's Disease and Related Disorders

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced it will present data from two of its movement disorder programs, including INGREZZA® (valbenazine) capsules, the first U.S. Food and Drug Administration...

NBIX : 85.79 (+2.23%)
SmarTrend Watching for Potential Rebound in Shares of Neurocrine Biosc After 2.64% Loss

Neurocrine Biosc (NASDAQ:NBIX) traded in a range yesterday that spanned from a low of $79.69 to a high of $80.01. Yesterday, the shares fell 2.6%, which took the trading range below the 3-day low of...

NBIX : 85.79 (+2.23%)
Neurocrine Biosciences to Present at Goldman Sachs 40th Annual Global Healthcare Conference

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the Goldman Sachs 40th Annual Global Healthcare Conference at 10:00 a.m. PT (1:00 p.m. ET) on Tuesday, June 11, 2019, in Rancho Palos Verdes,...

NBIX : 85.79 (+2.23%)
SmarTrend Watching for Potential Pullback in Shares of Neurocrine Biosc After 1.71% Gain

Neurocrine Biosc (NASDAQ:NBIX) traded in a range yesterday that spanned from a low of $83.69 to a high of $85.07. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high...

NBIX : 85.79 (+2.23%)
Biocom Appoints Additional Members to Board of Directors

Biocom, the association representing the California life science industry, today announced that it has added Matt Abernethy, chief financial officer of Neurocrine Biosciences, and Sabrina...

NBIX : 85.79 (+2.23%)
Not Ready to Rally

Not Ready to Rally

TGT : 87.39 (-0.46%)
TTEK : 71.23 (+0.01%)
OMC : 79.61 (+0.32%)
NBIX : 85.79 (+2.23%)
HPQ : 19.88 (-0.15%)
VEEV : 166.12 (+0.91%)
VRNT : 55.14 (-1.55%)
IMMR : 7.38 (+1.51%)
L : 53.17 (-0.69%)
TOL : 37.56 (-1.88%)
ANF : 16.03 (+3.49%)
SHAK : 67.48 (+0.66%)
WCG : 292.96 (+2.04%)
DVN : 26.33 (+2.17%)
LDOS : 78.18 (-0.84%)
AbbVie Launches ORILISSA(TM) (elagolix) 200 mg BID Dose for the Treatment of Moderate to Severe Pain Associated with Endometriosis

AbbVie (NYSE: ABBV), a global, research and development-driven biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), announced that ORILISSATM (elagolix) 200 mg twice...

NBIX : 85.79 (+2.23%)
ABBV : 78.83 (+0.18%)
Neurocrine Biosciences Presents New Data from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia, Demonstrating the Effect of Involuntary Movements on Patient Quality of Life

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced new data from RE-KINECT, the largest real-world screening study to date of patients with clinician-confirmed possible tardive dyskinesia (TD),...

NBIX : 85.79 (+2.23%)
Neurocrine Biosciences to Present New Quality-of-Life Data Analysis from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia Patients, at the 2019 American Psychiatric Association Annual Meeting

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that it will present a new quality-of-life data analysis from RE-KINECT, the largest real-world screening study of patients with clinician-confirmed...

NBIX : 85.79 (+2.23%)
Trade Anxieties Return with a Vengeance

Trade Anxieties Return with a Vengeance

UVXY : 33.58 (-1.47%)
BIDU : 114.15 (+0.95%)
NBIX : 85.79 (+2.23%)
VRTX : 173.87 (+2.14%)
LYV : 65.01 (+1.59%)
RCUS : 8.90 (+7.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade NBIX with:

Business Summary

Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The company's neuroscience, endocrine and immunology disciplines provide a unique biological understanding...

See More

Key Turning Points

2nd Resistance Point 85.49
1st Resistance Point 84.70
Last Price 85.79
1st Support Level 82.95
2nd Support Level 81.99

See More

52-Week High 126.98
Fibonacci 61.8% 103.20
Fibonacci 50% 95.85
Fibonacci 38.2% 88.50
Last Price 85.79
52-Week Low 64.72

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar